StudyFinder

Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors

Status: Recruiting

The purpose of this screening study is to collect samples to conduct the testing of specific human leukocyte antigen (HLA). TScan Therapeutics is developing cellular therapies across multiple solid tumors in which the eligibility criteria require that participants have specific HLA types. The results from this screening study will be used to determine if participants meet the eligibility criteria and could potentially be enrolled in a future TScan treatment study.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• have one of the following confirmed locally advanced (unresectable) or metastatic solid tumor: Head and neck cancer, cervical cancer, non-small cell lung cancer, melanoma, ovarian cancer, HPV positive anogenital cancer HPV positive anogenital cancers
Exclusion Criteria:

• undergoing anticancer therapy with curative intent
Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), anal, Cervical, genital, Head and Neck, HPV16, Melanoma, Non Small Cell Lung, Ovarian, Solid Tumor

Study Contact: Benjamin Manning - mann0233@umn.edu
Principal Investigator: Benjamin Manning
IRB Number: STUDY00019929
See this study on ClinicalTrials.gov

Back